{"task_id": "43cdac30b59e9222", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 142/464)", "text": " 1200 mg PO\ndaily \u00042 years\nAcute Liver Failure\n129\n\n--- Page 151 ---\nNON ALCOHOLIC STEATOHEPATITIS (NASH)\n\u0002\nASSOCIATIONS\nobesity, hyperlipidemia, diabetes,\nCushing\u2019s, TPN, high protein diets for weight loss,\namiodarone, tamoxifen\nSPECIFIC ENTITIES (CONT\u2019D)\n\u0002\nDIAGNOSIS\nliver biopsy\n\u0002\nTREATMENTS\nweight loss, metformin (experimental)\nHepatitis B\nNEJM 2004 350:11; NEJM 2008 359:14\nPATHOPHYSIOLOGY\nNATURAL HISTORY\nacute hepatitis ! chronic dis\nease develops in >90% of neonates, in 10% if 12 years\nold, and in <1% if >12 years old ! 12 20% with\nchronic hepatitis progress to cirrhosis in 5 years !\n20% with compensated cirrhosis progress to decom\npensation in 5 years and 6 15% with compensated\ncirrhosis progress to hepatocellular carcinoma. Life\ntime risk of hepatocellular carcinoma/death in patients\nwith chronic hepatitis is 40% for ? and 15% for /\nACUTE HEPATITIS B\nmay range from subclinical/\nanicteric hepatitis (70%) to icteric hepatitis (30%) and\neven fulminant hepatic failure (0.5 1%). Symptoms\nmay include fever, anorexia, rash, nausea, jaundice,\nRUQ tenderness, arthralgia, and arthritis. \"\" ALT and\nAST\nCHRONIC HEPATITIS B\n\u0002\nREPLICATIVE PHASE WITH IMMUNE TOLERANCE (only if\nvertical transmission)\nHBeAg positive, asympto\nmatic as lack of immune response in children. May\nlast 10 30 years\n\u0002\nREPLICATIVE\nPHASE\nWITH\nIMMUNE\nCLEARANCE\nHBeAg positive with seroconversion to HBeAb,\nmay be symptomatic with increased liver enzymes\ndue to immune response against HBV\n\u0002\nNON-REPLICATIVE\nPHASE\nHBeAb\npositive,\nlow\nlevel of viral replication. Usually normal liver\nenzymes\n\u0002\nSUSPECT PROGRESSION TO CIRRHOSIS\nif hypersplen\nism or impaired synthetic function (\" INR, \" bilir\nubin, hypoalbuminemia)\nGENOTYPES\nthere are currently eight different\ngenotypes (A to H)\nRISK\nFACTORS\nvertical\ntransmission,\nendemic\nareas, transfusions, dialysis, healthcare workers, IDU,\nhigh risk sex/homosexuals, body piercing, tattoos,\norgan transplantation\nRelated Topics\nAcute Liver Failure (p. 128)\nChronic Liver Failure (p. 132)\nHBV/HIV Co infection (p. 261)\nHepatitis C (p. 131)\nHepatoma (p. 205)\nCLINICAL FEATURES\nHISTORY\nsymptoms of liver failure (jaundice,\nbleeding,\ninfections,\nascites,\nconfusion),\nweight\nchange, risk factors of hepatitis (family history, sexual\nactivity, IDU, tattoos, piercing, healthcare worker,\ntransfusions, dialysis), past medical history (alcohol,\nHCV, HIV), medication history\nPHYSICAL\nliver examination, stigmata of chronic\nliver disease (see p. 132), weight\nEXTRAHEPATIC MANIFESTATIONS OF HBV\npoly\narteritis nodosa, membranous nephropathy, mem\nbranoproliferative glomerulonephritis\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, glucose, AST, ALT, ALP,\nbilirubin, INR, albumin, HBV serology (HBsAb,\nHBsAg, HBcIgM, HBcIgG to determine infection/\nimmune status, HBeAg, HBeAb, HBV DNA to see if\nactive replication), HAV serology, HCV serology,\nHDV serology, iron, TIBC, HIV serology\n\u0002\nIMAGING\nU/S abd\nSPECIAL\n\u0002\nLIVER BIOPSY\nDIAGNOSTIC ISSUES\nHEPATITIS B SEROLOGY\n\u0002 HBSAG\nhepatitis B surface antigen. Positive if\nactive infection\n\u0002 HBCIGM\nIgM antibody against hepatitis B core\nantigen. Suggestive of early infection (indicates\nthe window period) or reactivation\n\u0002 HBSAB\nantibody against hepatitis B surface anti\ngen. Positive if immunized (through past infection\nor vaccination)\n\u0002 HBCIGG\nIgG antibody against hepatitis B core\nantigen. Suggestive of hepatitis B exposure\n\u0002 HBEAG\nhepatitis B envelope protein. HBeAg\npositivity suggests high viral replication with high\ninfectivity. However, HBeAg negativity without\nHBeAb positivity suggests chronic HBV infection\nwith pre core mutants/promoter mutations, with a\nmore aggressive phenotype than HBeAg+ HBV,\nmore treatment failures, and progressive hepatic\nSPECIFIC ENTITIES (CONT\u2019D)\n130\nHepatitis B", "text_length": 3757, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 142/464)", "type": "chunk", "chunk_index": 141, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.441181", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.442071", "status": "complete", "chunks_added": 2}